|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 |
网站主页 >> 化工产品目录 >> >> 市场分析报告 |
市场分析报告 |
|
Therapeutic Class Overview: Treating Refractory Hematological Malignancies Targeting unmet needs in the treatment of cancer/ hematological malignancies through innovative drug development strategies have witnessed favorable outcomes. Over the past decade, Proteasome inhibitor, Velcade (bortezomib) and the immunomodulatory drugs ... Hematological Malignancies: Multiple Myeloma (MM) – Early and Robust Diagnosis along with New Treatment Options can have Considerable Impact on Management of the Disease While targeting unmet needs in the treatment of hematological malignancies/ cancer through innovative drug development strategies have witnessed favorable outcomes, the specific choice of the therapies is dependent on the identification of important ... Proto oncogene protein c-akt inhibitors - Pipeline Insight, 2022 ... liposomal Paxalisib Tucidinostat Capivasertib Miransertib Afuresertib Enzastaurin CU 05 API-2 Pravitinib Uprosertib ALM ... |